COMPARE · Data as of August 24, 2026
AUPH vs ONC
Verdict: Side-by-side breakdown using the Bull Rankings model. AUPH scored 72.6, ONC scored 69.9 — AUPH leads.
Compare another set
AUPH
Aurinia Pharmaceuticals Inc.
72.6
$16.65 · $2.2B
fundamentals as of
Score gap
2.7
AUPH leads
ONC
BeOne Medicines AG
69.9
$371.98 · $42.1B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestAUPH7.3x
- Fastest growthONC+34.3%
- Strongest balance sheetAUPH0.10
- Highest qualityAUPH74 / 100
- Largest discount to fair valueONC-19%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
AUPH
stronger →← stronger
ONC
74
Qualityreturns · margins · balance sheet
61
60
Growthrevenue & earnings expansion
97
86
Valuevaluation vs sector peers
58
AUPH is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
AUPH
ONC
$175mC
FCF
$1.3bC+
+20.4%A-
Rev
+34.3%A
0.10B+
D/E
0.40B
7.3xA
P/E
66.7xC
0.58A-
PEG
1.07B+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
AUPH
ONC
9% below
Price vs fair valuelower is cheaper
19% below
~6%/yr
Growth the price implies10-yr FCF · lower = less priced in
~9%/yr
-3%
1-yr DCF upside
-7%
+10%
5-yr DCF upside
+24%
+30%
10-yr DCF upside
+91%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AUPH
Why this score
- Earnings outpace cash
ONC
Why this score
- Diluting shareholders
The companies
AUPHAurinia Pharmaceuticals Inc.
Why now
Biotechnology · market cap $2.2b. 14% off the 52-week high of $19.25. Revenue growing +20%, comfortably above the S&P median. PEG 0.58 — paying under fair value for the growth rate. 6 sell-side analysts rate this a Buy with a mean 1-yr target of $18.17 (implying +9% upside).
Moat
ROE 51% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Beta 1.40 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ONCBeOne Medicines AG
Why now
Biotechnology · market cap $42.1b. 3% off the 52-week high of $385.22. Revenue growing +34% — in hypergrowth territory. 27 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $433.02 (implying +16% upside).
Moat
ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 66.7x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Reimbursement risk — even an approved drug can fail commercially if payors don't reimburse; pricing pressure from Medicare and large PBMs has been accelerating since 2024.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where AUPH and ONC diverge
On the headline score the gap is 2.7 points in favor of AUPH. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- GrowthAUPH 60.3 · ONC 96.8ONC +36.5
- ValueAUPH 85.7 · ONC 57.8AUPH +27.9
- QualityAUPH 74.0 · ONC 61.0AUPH +13.0
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.